Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program
March 29, 2016 07:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 29, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that...
Ohr Pharmaceutical to Present at Upcoming Investment Conferences
March 02, 2016 14:45 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive...
Ohr Pharmaceutical Reports First Quarter 2016 Financial and Business Results
February 09, 2016 16:01 ET
|
Ohr Pharmaceutical, Inc.
Conference Call Today at 5:00pm Eastern Time NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported...
Ohr Pharmaceutical to Present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York
February 09, 2016 09:48 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive...
Ohr Pharmaceutical to Announce First Quarter 2016 Financial Results on February 9
February 03, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for...
Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results
December 10, 2015 16:01 ET
|
Ohr Pharmaceutical, Inc.
OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016
Conference Call and Webcast with Slides, Today at 5:00pm Eastern Time
NEW YORK, Dec. 10,...
Ohr Pharmaceutical to Report Fiscal 2015 Financial Results on Thursday, December 10
December 08, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 8, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for fiscal...
Ohr Pharmaceutical Announces Positive Preclinical Data in SKS Sustained Release Ocular Program
December 03, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced positive results from a preclinical study...
Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting
November 16, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
Occult CNV Size in Wet-AMD is Predictive of Success of OHR-102 Combination Therapy
Results Drive Patient Selection and Design for Phase 3 Program
NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ohr...
Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology
November 12, 2015 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the company has submitted a Special Protocol...